| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10112942 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(13 years from now) | |
| US10584124 | LOXO ONCOL ELI LILLY | Crystalline forms |
Oct, 2038
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10172851 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(13 years from now) | |
| US10137124 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(13 years from now) | |
| US10786489 | LOXO ONCOL ELI LILLY | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
Oct, 2038
(14 years from now) | |
Retevmo is owned by Loxo Oncol Eli Lilly.
Retevmo contains Selpercatinib.
Retevmo has a total of 5 drug patents out of which 0 drug patents have expired.
Retevmo was authorised for market use on 08 May, 2020.
Retevmo is available in capsule;oral dosage forms.
Retevmo can be used as treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive refractory differentiated thyroid cancer who require systemic therapy and are radioactive iodine-refractory, treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with a rearranged during transfection (ret) gene fusion, as detected by an fda-approved test, treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer, treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (mtc) with a ret mutation, as detected by an fda-approved test, who require systemic therapy.
Drug patent challenges can be filed against Retevmo from 08 May, 2024.
The generics of Retevmo are possible to be released after 10 October, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2025 |
| Orphan Drug Exclusivity(ODE-301) | May 08, 2027 |
| Orphan Drug Exclusivity(ODE-303) | May 08, 2027 |
| Orphan Drug Exclusivity(ODE-302) | May 08, 2027 |
| Orphan Drug Exclusivity(ODE-409) | Sep 21, 2029 |
| Orphan Drug Exclusivity(ODE-412) | Sep 21, 2029 |
Drugs and Companies using SELPERCATINIB ingredient
NCE-1 date: 08 May, 2024
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic medullary th...
Dosage: CAPSULE;ORAL
RETEVMO family patents
